Please ensure Javascript is enabled for purposes of website accessibility

Here's Why uniQure N.V.'s Stock Spiked Today

By George Budwell - Jan 7, 2016 at 9:55AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

UniQure N.V.'s stock rose on Thursday on the back of positive clinical news.

Source: Flickr via user South Florida Sun

What: UniQure N.V. (QURE -28.90%), a small-cap gene therapy company, saw its shares climb by as much as 12% on unusually high volume Thursday morning. The catalyst behind this move was the news that the company's experimental treatment for hemophilia B, AMT-060, increased the blood clotting ability of the first two patients treated with the therapy in a small ongoing clinical trial. 

So what: The company believes that these initial results suggest that AMT-060 is generally safe and could eventually turn out to be an important new treatment for hemophilia B. If that line holds, AMT-060 could one day become a huge value driver for the company, especially since it is targeting a rare bleeding disorder with few treatment options.

Now what: Looking ahead, we should learn more about this experimental gene therapy at an upcoming scientific conference in the second quarter of 2016, according to the company. Until then, investors may not want to make too much of these preliminary results

While these data are certainly promising, it's important to remember that the stocks of other gene therapy companies like bluebird bio (BLUE 7.07%) have skyrocketed in the past after only a handful of patients were treated in small early stage trials. Later on, however, bluebird's stock -- along with some of its peers -- would end up up giving back a fair amount of these eye-popping gains because the emerging clinical data started to look less and less compelling as more patients were treated.

In short, gene therapy has a long history of producing impressive results early on, only to fade as the sample size increases. That's not to say that the same scenario will play out with AMT-060, but it's an issue worth understanding before picking up shares in any gene therapy company. 

George Budwell has no position in any stocks mentioned. The Motley Fool recommends Bluebird Bio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

uniQure N.V. Stock Quote
uniQure N.V.
QURE
$18.16 (-28.90%) $-7.38
bluebird bio, Inc. Stock Quote
bluebird bio, Inc.
BLUE
$5.99 (7.07%) $0.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.